EI                                                   sarcoma(134)
 _________________________________________________________________
  etoposide....... 100 mg/sqm/day IV over 1 h from day 1 to day 5.
  ifosfamide...... 1,800 mg/sqm IV  plus the loading dose of mesna 
                   (360 mg/sqm) started immediately after 
                   etoposide over 1 h, then oral mesna every 3 h 
                   times 6 each day from day 1 to day 5.
  FREQUENCY....... Repeat cycle every 3 weeks for a total of 12 
                   cycles or progression.


  reference...
    Miser JS.  Kinsella TJ.  Triche TJ.  Tsokos M.  Jarosinski P.  
    Forquer R.  Wesley R.  Magrath I. Ifosfamide with mesna 
    uroprotection and etoposide: an effective regimen in the 
    treatment of recurrent sarcomas and other tumors of children 
    and young adults. Journal of Clinical Oncology.  5(8):1191-8, 
    1987 Aug. 
  abstract...
    One hundred twenty-four children and young adults with 
    recurrent tumors, predominantly sarcomas, were treated with 
    the combination of ifosfamide, etoposide, and the 
    uroprotector, mesna (2-mercaptoethane sulphonate), in a phase 
    II trial. The treatment regimen consisted of 12 cycles of 
    therapy administered every 3 weeks. After evaluation of the 
    tumor response to chemotherapy alone, radiation or surgery was 
    used to eradicate residual sites of metastatic disease where 
    possible. At the present time, 77 patients are evaluable for 
    response to the chemotherapy; 43 of the patients have 
    experienced a significant reduction in the tumor size in 
    response to the chemotherapy alone (39 partial responses [PR] 
    and four complete responses [CR]). Sixteen of 17 patients with 
    Ewing's sarcoma, nine of 13 with rhabdomyosarcoma, four of 
    eight with peripheral neuroepithelioma, three of eight with 
    osteosarcoma, and 11 of 31 with other tumors have responded 
    with a PR or CR. The toxicity of the regimen was acceptable. 
    Moderate or severe toxicity evaluated on a per cycle basis 
    included: neutropenia, 97%; thrombocytopenia, 32%; 
    nephrotoxicity, less than 1%; mucositis, 1%; neurologic 
    toxicity, 2%; nausea and vomiting, 13%; hemorrhagic cystitis, 
    less than 1%. Fever was present after 33% of cycles and sepsis 
    following 7%. One patient died due to sepsis and pancytopenia. 
    At the present time, only seven of the 43 patients who 
    responded to the chemotherapy regimen have relapsed, with a 
    median follow-up of 10 weeks after the response. This drug 
    combination is highly active in the treatment of recurrent 
    sarcomas and other tumors in children and young adults.